Search

Displaying results 6671 - 6680 of 10000 in total
  1. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  2. Drug

    Butyrylcholinesterase

    go.drugbank.com/drugs/DB06352
    Investigational

  3. Drug

    Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15683
    ApprovedInvestigational

  4. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  5. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others.

  6. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).

  7. Drug

    Pegvisomant

    go.drugbank.com/drugs/DB00082
    ApprovedInvestigational

    Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediat...

  8. Drug

    Kitasamycin

    go.drugbank.com/drugs/DB09309
    Experimental

    Kitasamycin is a macrolide antibiotic derived from <em>Streptomyces kitasatoensis</em>.

  9. Drug

    Fosifloxuridine nafalbenamide

    go.drugbank.com/drugs/DB14859
    Investigational

    Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).

  10. Drug

    Ieramilimab

    go.drugbank.com/drugs/DB16419
    Investigational

    Ieramilimab is under investigation in clinical trial NCT02460224 (Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.).